Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Adicet Bio Inc (ACET)

Adicet Bio Inc (ACET)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Apr 28, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on April...

ACET : 1.5900 (+5.30%)
Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference Business Wire - Thu Apr 13, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 1.5900 (+5.30%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Mar 31, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on March...

ACET : 1.5900 (+5.30%)
Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress Business Wire - Wed Mar 15, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights...

ACET : 1.5900 (+5.30%)
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit Business Wire - Thu Mar 9, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 1.5900 (+5.30%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue Feb 28, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on February...

ACET : 1.5900 (+5.30%)
Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference Business Wire - Wed Feb 1, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief...

ACET : 1.5900 (+5.30%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Tue Jan 31, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on January...

ACET : 1.5900 (+5.30%)
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Business Wire - Fri Dec 30, 2022

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced it granted inducement awards on December...

ACET : 1.5900 (+5.30%)
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) Business Wire - Sat Dec 10, 2022

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced positive safety and efficacy data...

ACET : 1.5900 (+5.30%)

Barchart Exclusives

Tesla Stock Forecast Post-Q2 Earnings: 'Present Imperfect, Future Uncertain' Barchart - 31 minutes ago
Tesla stock crashed following its Q2 earnings earlier this week. Here are the key takeaways from the report, and the forecast for the company amid a challenging macro environment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot